 Putting all the speculations at bay, Merck Co Inc NYSE: MRK has agreed to acquire Acceleron Pharma Inc NASDAQ: XLRN for 180 per share in cash for an approximate total equity value of 11.5 billion. Related Link: Merck Reportedly Lead Bidder In 11B Acceleron Buyout: WSJ. 